Back to search results

Structured Personalized Oxygen and Supportive Therapies for Dyspnea in Oncology (SPOT-ON)

This study is looking at how a treatment called Structured Personalized Oxygen and Supportive Therapies for Dyspnea in Oncology (SPOT-ON) affects shortness of breath (dyspnea) in cancer patients. SPOT-ON includes learning breathing, relaxation, posture, and distraction techniques, and trying different oxygen therapies like high-flow nasal cannula. You could be eligible if you are 18 or older, have cancer, are in the hospital, have shortness of breath at rest (a score of 4 or more on a 0-10 scale), and speak English or Spanish. The study aims to see if SPOT-ON can reduce the intensity of your shortness of breath within 24 hours. The study plans to enroll 150 participants, but its current status is unclear.

Study design
This interventional study aims to enroll 150 participants to compare two approaches to SPOT-ON treatment: an early start and a delayed start.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Safety and adverse events will be measured through study completion, which is an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06336642

Structured Personalized Oxygen and Supportive Therapies for Dyspnea in Oncology

Recruiting
PHASE2Ages 18+InterventionalSupportive care
M.D. Anderson Cancer Center
~150 participants
Updated 2026-08-04 on ClinicalTrials.gov
What's tested:SPOT-ON Early StartSPOT-ON Delayed Start

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Primary Outcome Measure: 1.Safety and adverse events (AEs)
Measured over [Time Frame: Through study completion; an average of 1 year.]

Conditions

Dyspnea

Explore related trials

DyspneaMalignant Neoplasm

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • David Hui, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

David Hui, MD
[email protected]
(713) 792-6258
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosis of cancer
Age 18 or older.
Admitted to a medical floor.
Dyspnea intensity at rest of at least 4 on a 0-10-point NRS (where 0 = none, 10 = worst).
Speak English or Spanish.

Exclusion

Hemodynamic instability requiring active Merit Team or ICU team involvement.
Delirium as per clinical team's assessment in the Electronic Health Record (EHR).
Severe hypoxemia (SpO2 \< 90% despite supplemental oxygen of up to 6 L/min).
Continuous positive airway pressure (CPAP) use for obstructive sleep apnea, actively using \>10 hours a day.
Respiratory failure necessitating mechanical ventilation (i.e., HFNC or NIV), and planned thoracentesis within 72 hours of enrollment.
Patients with known pregnancy.

What this trial measures

  • Primary Outcome Measure: 1.Safety and adverse events (AEs)[Time Frame: Through study completion; an average of 1 year.]

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)